Table I.
Results of univariate analyses to determine factors predictive of recurrence-free survival in 90 patients with aggressive fibromatosis.
| Estimated RFS rate, % (95% CI) | ||||||
|---|---|---|---|---|---|---|
| Variable | Total no. of patients | No. of patients with recurrences | 1-year | 2-year | 5-year | P-value (log-rank)a |
| Patient age, years | 0.794 | |||||
| <50 | 61 | 31 | 78.5 (65.9–86.9) | 70.2 (56.9–80.1) | 54.5 (40.4–66.6) | |
| ≥50 | 29 | 14 | 86.2 (67.3–94.6) | 57.7 (37.6–73.4) | 46.6 (27.6–63.6) | |
| Gender | 0.315 | |||||
| Male | 37 | 22 | 83.5 (67.0–92.2) | 72.2 (54.4–84.0) | 59.2 (40.7–73.7) | |
| Female | 53 | 23 | 79.2 (65.7–87.9) | 62.3 (47.8–73.8) | 47.8 (33.6–60.7) | |
| Tumor site | 0.387 | |||||
| Extremity | 51 | 21 | 78.4 (64.4–87.4) | 58.5 (43.7–70.6) | 40.0 (25.9–53.8) | 0.074b |
| Abdominal cavity | 14 | 10 | 85.7 (53.9–96.2) | 78.6 (47.2–92.5) | 78.6 (47.2–92.5) | 0.147c |
| Head/neck | 7 | 3 | 57.1 (17.2–83.7) | 57.1 (17.2–83.7) | 57.1 (17.2–83.7) | 0.530d |
| Truncal wall | 18 | 11 | 94.1 (65.0–99.1) | 82.4 (54.7–93.9) | 63.5 (35.9–81.8) | 0.241e |
| Tumor size, cm | 0.799 | |||||
| <5 | 26 | 15 | 84.3 (63.3–93.8) | 63.5 (41.5–79.1) | 59.0 (37.1–75.6) | |
| ≥5 | 64 | 30 | 79.7 (67.6–87.7) | 67.2 (54.2–77.2) | 50.3 (37.2–62.0) | |
| Previous history of trauma at disease site | 0.296 | |||||
| Yes | 15 | 5 | 80.0 (50.0–93.1) | 53.3 (26.3–74.4) | 45.7 (20.1–68.3) | |
| No | 75 | 40 | 81.2 (70.3–88.4) | 68.9 (57.0–78.1) | 53.3 (40.8–64.3) | |
a
Log-rank test for equality of survivor functions
b
Extremity vs. non-extremity tumors
c
Abdominal cavity vs. non-abdominal cavity tumors
d
Head/neck vs. non-head/neck tumors
e
Truncal wall vs. Non-truncal wall tumors. RFS, recurrence-free survival; CI, confidence interval.